Charles River Laboratories International Stock Surges 11%, With A 5-Day Winning Spree
Charles River Laboratories International (CRL) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 11% return. The company has gained about $851 Mil in value over the last 5 days, with its current market capitalization at about $8.8 Bil. The stock remains 3.1% below its value at the end of 2024. This compares with year-to-date returns of 15.8% for the S&P 500.
Charles River Laboratories recently surged, propelled by an Argus upgrade to ‘Buy’ and the lifting of a regulatory cloud following SEC clearance in its probe. Investors are also eyeing strategic AI partnerships and portfolio streamlining to enhance long-term growth.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There are several things to fear in CRL stock given its overall Weak operating performance and financial condition. This isn’t appropriately reflected in the stock’s Moderate valuation which is why we think it is Unattractive (see Buy or Sell CRL).
For quick background, CRL provides drug discovery, safety testing, and research models, along with early discovery services and in vitro testing for pharmaceuticals and consumer products.
Comparing CRL Stock Returns With The S&P 500
The following table summarizes the return for CRL stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CRL | S&P 500 |
|---|---|---|
| 1D | 0.5% | 0.7% |
| 5D (Current Streak) | 10.7% | 2.6% |
| 1M (21D) | -4.8% | -1.1% |
| 3M (63D) | 9.6% | 4.8% |
| YTD 2025 | -3.1% | 15.8% |
| 2024 | -21.9% | 23.3% |
| 2023 | 8.5% | 24.2% |
| 2022 | -42.2% | -19.4% |
However, big gains can follow sharp reversals – but how has CRL behaved after prior drops? See CRL Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 136 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 20 | 7 |
| 4D | 94 | 0 |
| 5D | 14 | 0 |
| 6D | 3 | 0 |
| 7D or more | 5 | 1 |
| Total >=3 D | 136 | 8 |
Key Financials for Charles River Laboratories International (CRL)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $4.1 Bil | $4.0 Bil |
| Operating Income | $617.3 Mil | $442.3 Mil |
| Net Income | $474.6 Mil | $10.3 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.0 Bil | $1.0 Bil |
| Operating Income | $100.1 Mil | $133.8 Mil |
| Net Income | $52.3 Mil | $54.4 Mil |
While CRL stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.